USA flag logo/image

An Official Website of the United States Government

Company Information:

Address: 1044 E CHESTNUT ST
LOUISVILLE, KY 40204-1019
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $277,707.00 1
STTR Phase I $122,978.00 1
STTR Phase II $963,666.00 1

Award List:

New anti-complement therapy to reduce reperfusion injury

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Principal Investigator: Claudio Maldonado
Award Amount: $122,978.00
RI Contact: N/A
DESCRIPTION (provided by applicant): The purpose of this proposal is to provide proof-of-concept that a novel therapy that prevents complement activation could be effective in reducing ischemia reperfusion injury (IRI) in transplanted organs. Complement activation after IRI in transplanted organs… More

New anti-complement therapy to reduce reperfusion injury: Phase II

Award Year / Program / Phase: 2008 / STTR / Phase II
Agency: HHS
Research Institution: N/A
Principal Investigator:
Award Amount: $963,666.00
RI Contact: N/A
DESCRIPTION (provided by applicant): Tissue and organ transplantation procedures save and/or improve the lives of hundred of thousands of patients annually in the US. The goal of this research is to develop a local anti-complement therapy for donor organ e x vivo application that will reduce… More

Device for Delivery of Rolipram to Liver for Treatment of Alcoholic Liver Disease

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Philip Bauer – 502-569-1020
Award Amount: $277,707.00
DESCRIPTION (provided by applicant): Alcoholic Liver Disease (ALD) remains a leading cause of death from liver disease in the U.S., and there is still no FDA-approved therapy. Abnormal cytokine metabolism is a major feature of ALD. Elevated serum concentrations of tumor necrosis factor (TNF-) and… More